[go: up one dir, main page]

SMT202300352T1 - Derivati bipirazolici come inibitori di jak - Google Patents

Derivati bipirazolici come inibitori di jak

Info

Publication number
SMT202300352T1
SMT202300352T1 SM20230352T SMT202300352T SMT202300352T1 SM T202300352 T1 SMT202300352 T1 SM T202300352T1 SM 20230352 T SM20230352 T SM 20230352T SM T202300352 T SMT202300352 T SM T202300352T SM T202300352 T1 SMT202300352 T1 SM T202300352T1
Authority
SM
San Marino
Prior art keywords
jak inhibitors
bipyrazole derivatives
bipyrazole
derivatives
jak
Prior art date
Application number
SM20230352T
Other languages
English (en)
Inventor
Ganfeng Cao
Qun Li
Yun-Long Li
Song Mei
Ding-Quan Qian
Jincong Zhuo
Yongchun Pan
Zhongjiang Jia
Original Assignee
Incyte Holdings Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Holdings Corp filed Critical Incyte Holdings Corp
Publication of SMT202300352T1 publication Critical patent/SMT202300352T1/it

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
SM20230352T 2013-05-17 2014-05-16 Derivati bipirazolici come inibitori di jak SMT202300352T1 (it)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361824683P 2013-05-17 2013-05-17
EP20201593.9A EP3786162B1 (en) 2013-05-17 2014-05-16 Bipyrazole derivatives as jak inhibitors

Publications (1)

Publication Number Publication Date
SMT202300352T1 true SMT202300352T1 (it) 2024-01-10

Family

ID=50983151

Family Applications (5)

Application Number Title Priority Date Filing Date
SM20190223T SMT201900223T1 (it) 2013-05-17 2014-05-16 Sale di bipirazolo come inibitore di jak
SM20250397T SMT202500397T1 (it) 2013-05-17 2014-05-16 Derivati bipirazolici come inibitori di jak
SM20230352T SMT202300352T1 (it) 2013-05-17 2014-05-16 Derivati bipirazolici come inibitori di jak
SM20210040T SMT202100040T1 (it) 2013-05-17 2014-05-16 Derivati di bipirazolo come inibitori di jak
SM20170258T SMT201700258T1 (it) 2013-05-17 2014-05-16 Derivati di bipirazolo come inibitori di jak

Family Applications Before (2)

Application Number Title Priority Date Filing Date
SM20190223T SMT201900223T1 (it) 2013-05-17 2014-05-16 Sale di bipirazolo come inibitore di jak
SM20250397T SMT202500397T1 (it) 2013-05-17 2014-05-16 Derivati bipirazolici come inibitori di jak

Family Applications After (2)

Application Number Title Priority Date Filing Date
SM20210040T SMT202100040T1 (it) 2013-05-17 2014-05-16 Derivati di bipirazolo come inibitori di jak
SM20170258T SMT201700258T1 (it) 2013-05-17 2014-05-16 Derivati di bipirazolo come inibitori di jak

Country Status (36)

Country Link
US (8) US9382231B2 (it)
EP (6) EP3527263B1 (it)
JP (5) JP6415543B2 (it)
KR (4) KR102729910B1 (it)
CN (2) CN107698569B (it)
AR (2) AR096330A1 (it)
AU (5) AU2014265279B2 (it)
BR (1) BR112015028501B8 (it)
CA (1) CA2911536C (it)
CL (1) CL2015003355A1 (it)
CR (2) CR20190156A (it)
CY (3) CY1119105T1 (it)
DK (4) DK3786162T3 (it)
EA (2) EA039660B1 (it)
ES (5) ES2845210T3 (it)
FI (2) FI4275756T3 (it)
HK (1) HK1245769B (it)
HR (5) HRP20251220T1 (it)
HU (4) HUE063817T2 (it)
IL (4) IL242453B (it)
LT (5) LT3786162T (it)
ME (2) ME03355B (it)
MX (2) MX385187B (it)
MY (1) MY174788A (it)
PE (2) PE20200527A1 (it)
PH (2) PH12015502563B1 (it)
PL (4) PL3786162T3 (it)
PT (5) PT4275756T (it)
RS (5) RS64591B1 (it)
SG (2) SG10201709469SA (it)
SI (4) SI3786162T1 (it)
SM (5) SMT201900223T1 (it)
TR (1) TR201905814T4 (it)
TW (4) TWI719401B (it)
UA (1) UA117830C2 (it)
WO (1) WO2014186706A1 (it)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1966202E (pt) 2005-12-13 2012-01-03 Incyte Corp Pirrolo[2,3-b] pirimidinas e pirrolo[2,3-b]piridinas substituídas com heteroarilo como inibidores de janus quinase
RS53245B2 (sr) 2007-06-13 2022-10-31 Incyte Holdings Corp Soli inhibitora janus kinaze (r)-3-(4-(7h-pirolo(2,3-d) pirimidin-4-il)-1h-pirazol-1-il)-3-ciklopentilpropan-nitrila
TW201100429A (en) 2009-05-22 2011-01-01 Incyte Corp N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
PL2432472T3 (pl) 2009-05-22 2020-03-31 Incyte Holdings Corporation 3-[4-(7H-Pirolo[2,3-d]pirymidyn-4-ylo)-1H-pirazol-1-ilo]oktano- lub heptano-nitryle jako inhibitory JAK
ME01838B (me) 2009-06-29 2014-12-20 Lncyte Holdings Corp Pirimidinoni kao inhibitori pi3k
TW201113285A (en) 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
MX354212B (es) 2010-03-10 2018-02-19 Incyte Corp Derivados de piperidin-4-il azetidina como inhibidores de janus cinasa 1 (jak1).
EA202091303A3 (ru) 2010-05-21 2021-05-31 Инсайт Холдингс Корпорейшн Композиция ингибитора jak для местного применения
CA2818542A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
JP5961187B2 (ja) 2010-12-20 2016-08-02 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｐｉ３ｋ阻害剤としてのｎ−（１−（置換フェニル）エチル）−９ｈ−プリン−６−アミン
CN103797010B (zh) 2011-06-20 2016-02-24 因塞特控股公司 作为jak抑制剂的氮杂环丁烷基苯基、吡啶基或吡嗪基甲酰胺衍生物
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
SI3513793T1 (sl) 2011-09-02 2021-07-30 Incyte Holdings Corporation Heterociklilamini kot zaviralci PI3K
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
US9193733B2 (en) 2012-05-18 2015-11-24 Incyte Holdings Corporation Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
BR112015009942A2 (pt) 2012-11-01 2017-07-11 Incyte Corp derivados de tiofeno fundidos tricíclicos como inibidores de jak
NZ708157A (en) 2012-11-15 2019-07-26 Incyte Holdings Corp Sustained-release dosage forms of ruxolitinib
TWI634121B (zh) 2013-03-06 2018-09-01 英塞特控股公司 用於製備ｊａｋ抑制劑之方法及中間物
WO2014186706A1 (en) 2013-05-17 2014-11-20 Incyte Corporation Bipyrazole derivatives as jak inhibitors
MX394928B (es) 2013-08-07 2025-03-24 Incyte Holdings Corp Formas de dosificacion de liberacion prolongada para un inhibidor de jak 1 (cinasa de janus 1).
SG11201607083VA (en) * 2014-02-28 2016-09-29 Incyte Corp Jak1 inhibitors for the treatment of myelodysplastic syndromes
HRP20201887T1 (hr) 2014-04-08 2021-02-05 Incyte Corporation LIJEČENJE B-STANIČNIH MALIGNITETA S KOMBINACIJOM INHIBITORA JAK i PI3K
SG11201609016VA (en) 2014-04-30 2016-11-29 Incyte Corp Processes of preparing a jak1 inhibitor and new forms thereto
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
WO2015191677A1 (en) 2014-06-11 2015-12-17 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
US9421199B2 (en) 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
WO2016172712A2 (en) 2015-04-23 2016-10-27 Sydnexis, Inc. Ophthalmic composition
US9586949B2 (en) 2015-02-09 2017-03-07 Incyte Corporation Aza-heteroaryl compounds as PI3K-gamma inhibitors
MA41607B1 (fr) 2015-02-27 2021-01-29 Incyte Corp Sels d'un inhibiteur de pi3k et procédés de préparation de ces sels
US9732097B2 (en) 2015-05-11 2017-08-15 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
WO2016183063A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Crystalline forms of a pi3k inhibitor
WO2016196367A1 (en) 2015-05-29 2016-12-08 Sydnexis, Inc. D2o stabilized pharmaceutical formulations
AR106595A1 (es) 2015-11-06 2018-01-31 Incyte Corp COMPUESTOS HETEROCÍCLICOS COMO INHIBIDORES DE PI3K-g
EP3792256B1 (en) 2016-01-05 2024-10-23 Incyte Corporation Pyridine compounds as pi3k-gamma inhibitors
TW201803871A (zh) 2016-06-24 2018-02-01 英塞特公司 作為ＰＩ３Ｋ-γ抑制劑之雜環化合物
CN107759623B (zh) * 2016-08-23 2020-08-14 苏州旺山旺水生物医药有限公司 Jak抑制剂的中间体及其制备方法
SG11201901954XA (en) * 2016-09-06 2019-04-29 Hoffmann La Roche 8-(azetidin-1-yl)-[1,2,4]triazolo[1,5-a]pyridinyl compounds, compositions and methods of use thereof
MX2020003862A (es) 2017-10-18 2020-08-13 Incyte Corp Derivados condensados de imidazol sustituidos por grupos hidroxi terciarios como inhibidores de fosfoinositido 3-cinasas gamma (pi3k-gamma).
AR113922A1 (es) 2017-12-08 2020-07-01 Incyte Corp Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas
WO2019152374A1 (en) 2018-01-30 2019-08-08 Incyte Corporation Processes for preparing (1 -(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one)
WO2019161098A1 (en) 2018-02-16 2019-08-22 Incyte Corporation Jak1 pathway inhibitors for the treatment of cytokine-related disorders
US11584961B2 (en) 2018-03-30 2023-02-21 Incyte Corporation Biomarkers for inflammatory skin disease
HUE067471T2 (hu) * 2018-03-30 2024-10-28 Incyte Corp Gennyes verejtékmirigy-gyulladás kezelése jak inhibitorok alkalmazásával
US11372003B2 (en) 2018-04-13 2022-06-28 Incyte Corporation Biomarkers for graft-versus-host disease
CN108484468A (zh) * 2018-05-11 2018-09-04 南京大学 芳基氮杂环丁烷类化合物的制备方法
BR112020024427A2 (pt) 2018-06-01 2021-03-23 Incyte Corporation regime de dosagem para o tratamento de distúrbios relacionados a pi3k
CR20250050A (es) 2018-09-05 2025-03-19 Incyte Corp Formas cristalinas de un inhibidor de fosfoinositida 3–quinasa (pi3k) (divisional 2021-0165)
KR20210109522A (ko) 2018-10-31 2021-09-06 인사이트 코포레이션 혈액 질환의 치료를 위한 병용 요법
KR20210116487A (ko) 2018-12-19 2021-09-27 인사이트 코포레이션 위장 질환의 치료를 위한 jak1 경로 억제제
IL285999B1 (en) 2019-03-05 2025-09-01 Incyte Corp JAK1 inhibitor pathway for the treatment of chronic lung allograft dysfunction
EP3941474A2 (en) 2019-03-19 2022-01-26 Incyte Corporation Biomarkers for vitiligo
KR20210142154A (ko) 2019-03-21 2021-11-24 옹쎄오 암 치료를 위한 키나제 억제제와 조합된 dbait 분자
KR20220088699A (ko) 2019-09-27 2022-06-28 디스크 메디슨, 인크. 골수섬유증 및 관련 상태의 치료 방법
EP4041204A1 (en) 2019-10-10 2022-08-17 Incyte Corporation Biomarkers for graft-versus-host disease
US12360120B2 (en) 2019-10-10 2025-07-15 Incyte Corporation Biomarkers for graft-versus-host disease
US11992490B2 (en) 2019-10-16 2024-05-28 Incyte Corporation Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP)
JP7518900B2 (ja) * 2019-10-16 2024-07-18 インサイト・コーポレイション 皮膚エリテマトーデス及び扁平苔癬（ｌｐ）の治療のためのｊａｋ１阻害剤の使用
JP2023500906A (ja) 2019-11-08 2023-01-11 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
JP2023528223A (ja) 2020-05-13 2023-07-04 ディスク・メディシン・インコーポレイテッド 骨髄線維症を処置するための抗ヘモジュベリン（ｈｊｖ）抗体
JP2023528868A (ja) * 2020-06-02 2023-07-06 インサイト・コーポレイション Ｊａｋ１阻害剤の調製プロセス
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
WO2022040180A1 (en) 2020-08-18 2022-02-24 Incyte Corporation Process and intermediates for preparing a jak inhibitor
BR112023002939A2 (pt) 2020-08-18 2023-04-25 Incyte Corp Processo e intermediários para preparar um inibidor de jak1
CN112159394B (zh) * 2020-10-09 2021-10-22 嘉兴特科罗生物科技有限公司 一种作为jak激酶抑制剂的小分子化合物及其用途
PT4255442T (pt) 2020-12-04 2025-05-19 Incyte Corp Inibidor de jak com um análogo da vitamina d para o tratamento de doenças da pele
JP2023552452A (ja) * 2020-12-08 2023-12-15 インサイト・コーポレイション 白斑治療用のｊａｋ１経路阻害薬
CN114099514A (zh) * 2020-12-29 2022-03-01 上海岸阔医药科技有限公司 预防或治疗egfr功能异常相关的副作用的方法
TW202237083A (zh) 2021-01-11 2022-10-01 美商英塞特公司 包含ｊａｋ路徑抑制劑及ｒｏｃｋ抑制劑之組合療法
US12268667B2 (en) 2021-05-03 2025-04-08 Incyte Corporation JAK1 pathway inhibitors for the treatment of prurigo nodularis
JP2024526762A (ja) 2021-07-12 2024-07-19 インサイト・コーポレイション Ｊａｋ阻害剤を調製するためのプロセス及び中間体
US20240058343A1 (en) 2022-08-05 2024-02-22 Incyte Corporation Treatment of urticaria using jak inhibitors
TW202438061A (zh) 2023-03-16 2024-10-01 美商英塞特公司 用於治療氣喘之ｊａｋ１路徑抑制劑
CN117186078A (zh) * 2023-11-06 2023-12-08 药康众拓(北京)医药科技有限公司 氘代氮杂环丁烷类jak抑制剂药物及用途
US20250325664A1 (en) 2024-04-22 2025-10-23 Incyte Corporation Combination therapy with an anti-colony stimulating factor 1 receptor antibody and a jak inhibitor

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60106847U (ja) 1983-12-27 1985-07-20 富士重工業株式会社 室外後写鏡
JP2650681B2 (ja) 1987-07-10 1997-09-03 株式会社ブリヂストン 空気ばね
JPH0515775Y2 (it) 1987-07-13 1993-04-26
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
BR9912938B1 (pt) 1998-08-11 2011-06-28 derivados de isoquinolina, composição que os compreende, processo para preparação e uso dos mesmos.
US6133031A (en) 1999-08-19 2000-10-17 Isis Pharmaceuticals Inc. Antisense inhibition of focal adhesion kinase expression
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
ES2225624T3 (es) 2000-06-28 2005-03-16 Smithkline Beecham Plc Procedimiento de molienda por via humeda.
ATE420879T1 (de) 2001-09-19 2009-01-15 Aventis Pharma Sa Indolizine als kinaseproteinhemmer
US7973031B2 (en) 2001-10-30 2011-07-05 Novartis Ag Staurosporine derivatives as inhibitors of FLT3 receptor tyrosine kinase activity
AR037647A1 (es) 2002-05-29 2004-12-01 Novartis Ag Derivados de diarilurea utiles para el tratamiento de enfermedades dependientes de la cinasa de proteina
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
CL2003002353A1 (es) 2002-11-15 2005-02-04 Vertex Pharma Compuestos derivados de diaminotriazoles, inhibidores d ela proteina quinasa; composicion farmaceutica; procedimiento de preparacion; y su uso del compuesto en el tratamiento de enfermedades de desordenes alergicos, proliferacion, autoinmunes, condic
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
PE20050952A1 (es) 2003-09-24 2005-12-19 Novartis Ag Derivados de isoquinolina como inhibidores de b-raf
JP2008520612A (ja) 2004-11-24 2008-06-19 ノバルティス アクチエンゲゼルシャフト ＪＡＫ阻害剤およびＢｃｒ−Ａｂｌ、Ｆｌｔ−３、ＦＡＫまたはＲＡＦキナーゼ阻害剤のうち少なくとも１個の組合せ
PT1966202E (pt) 2005-12-13 2012-01-03 Incyte Corp Pirrolo[2,3-b] pirimidinas e pirrolo[2,3-b]piridinas substituídas com heteroarilo como inibidores de janus quinase
CL2008001709A1 (es) 2007-06-13 2008-11-03 Incyte Corp Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
RS53245B2 (sr) 2007-06-13 2022-10-31 Incyte Holdings Corp Soli inhibitora janus kinaze (r)-3-(4-(7h-pirolo(2,3-d) pirimidin-4-il)-1h-pirazol-1-il)-3-ciklopentilpropan-nitrila
WO2009064835A1 (en) * 2007-11-16 2009-05-22 Incyte Corporation 4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin-2-amines as janus kinase inhibitors
BRPI0909040B8 (pt) * 2008-03-11 2021-05-25 Incyte Holdings Corp derivados de azetidina e ciclobutano, seus usos, e composição
CL2009001884A1 (es) 2008-10-02 2010-05-14 Incyte Holdings Corp Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
JOP20190231A1 (ar) 2009-01-15 2017-06-16 Incyte Corp طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به
PL2432472T3 (pl) 2009-05-22 2020-03-31 Incyte Holdings Corporation 3-[4-(7H-Pirolo[2,3-d]pirymidyn-4-ylo)-1H-pirazol-1-ilo]oktano- lub heptano-nitryle jako inhibitory JAK
TW201100429A (en) 2009-05-22 2011-01-01 Incyte Corp N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
TW201113285A (en) 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
ES2435491T3 (es) 2009-10-09 2013-12-19 Incyte Corporation Derivados de hidroxilo, ceto y glucurónido de 3-(4-(7H-pirrolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il)-3-ciclopentilpropanonitrilo
CN102844317B (zh) 2010-02-18 2015-06-03 因西特公司 作为Janus激酶抑制剂的环丁烷和甲基环丁烷衍生物
MX354212B (es) 2010-03-10 2018-02-19 Incyte Corp Derivados de piperidin-4-il azetidina como inhibidores de janus cinasa 1 (jak1).
UA109131C2 (ru) * 2010-04-14 2015-07-27 Еррей Біофарма Інк. 5,7-ЗАМЕЩЕННЫЕ ИМИДАЗО[1,2-c]ПИРИМИДИНЫ КАК ИНГИБИТОРЫ JAK-КИНАЗ
EA202091303A3 (ru) 2010-05-21 2021-05-31 Инсайт Холдингс Корпорейшн Композиция ингибитора jak для местного применения
WO2012068440A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
CA2818542A1 (en) * 2010-11-19 2012-05-24 Incyte Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
EP2649061B1 (en) 2010-12-10 2015-05-13 Rottapharm Biotech S.r.l. Pyridine amide derivatives as ep4 receptor antagonists
EP2678686B1 (en) 2011-02-24 2017-10-11 Massachusetts Institute of Technology ALTERNATIVELY SPLICED mRNA ISOFORMS AS PROGNOSTIC INDICATORS FOR METASTATIC CANCER
CN103797010B (zh) 2011-06-20 2016-02-24 因塞特控股公司 作为jak抑制剂的氮杂环丁烷基苯基、吡啶基或吡嗪基甲酰胺衍生物
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
US9394282B2 (en) 2011-09-22 2016-07-19 Merck Sharp & Dohme Corp. Pyrazole carboxamides as Janus kinase inhibitors
US9193733B2 (en) * 2012-05-18 2015-11-24 Incyte Holdings Corporation Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
BR112015009942A2 (pt) 2012-11-01 2017-07-11 Incyte Corp derivados de tiofeno fundidos tricíclicos como inibidores de jak
NZ708157A (en) 2012-11-15 2019-07-26 Incyte Holdings Corp Sustained-release dosage forms of ruxolitinib
TWI634121B (zh) 2013-03-06 2018-09-01 英塞特控股公司 用於製備ｊａｋ抑制劑之方法及中間物
JO3603B1 (ar) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
US9371282B2 (en) 2013-05-17 2016-06-21 Centrexion Therapeutics Corporation Somatostatin receptor subtype 4 (SSTR4) agonists
WO2014186706A1 (en) 2013-05-17 2014-11-20 Incyte Corporation Bipyrazole derivatives as jak inhibitors
EA201592126A1 (ru) 2013-05-17 2016-05-31 Ф. Хоффманн-Ля Рош Аг 6-мостиковые гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b
EP2803668A1 (en) 2013-05-17 2014-11-19 Boehringer Ingelheim International Gmbh Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles
MX394928B (es) 2013-08-07 2025-03-24 Incyte Holdings Corp Formas de dosificacion de liberacion prolongada para un inhibidor de jak 1 (cinasa de janus 1).
SG11201607083VA (en) 2014-02-28 2016-09-29 Incyte Corp Jak1 inhibitors for the treatment of myelodysplastic syndromes
SG11201609016VA (en) 2014-04-30 2016-11-29 Incyte Corp Processes of preparing a jak1 inhibitor and new forms thereto
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
JP6697466B2 (ja) 2014-12-16 2020-05-20 ノバルティス アーゲー ＬｐｘＣ阻害剤としてのイソオキサゾールヒドロキサム酸化合物
WO2019161098A1 (en) 2018-02-16 2019-08-22 Incyte Corporation Jak1 pathway inhibitors for the treatment of cytokine-related disorders
JP2023528868A (ja) 2020-06-02 2023-07-06 インサイト・コーポレイション Ｊａｋ１阻害剤の調製プロセス
PT4255442T (pt) 2020-12-04 2025-05-19 Incyte Corp Inibidor de jak com um análogo da vitamina d para o tratamento de doenças da pele
JP2023552452A (ja) 2020-12-08 2023-12-15 インサイト・コーポレイション 白斑治療用のｊａｋ１経路阻害薬

Also Published As

Publication number Publication date
JP7126741B2 (ja) 2022-08-29
JP2021008493A (ja) 2021-01-28
RS58743B1 (sr) 2019-06-28
EP4275756A2 (en) 2023-11-15
KR102341908B1 (ko) 2021-12-23
EP4620528A3 (en) 2025-11-26
PT3527263T (pt) 2021-02-01
US9382231B2 (en) 2016-07-05
NZ753636A (en) 2020-11-27
IL264409B (en) 2021-05-31
RS67392B1 (sr) 2025-11-28
JP2019011364A (ja) 2019-01-24
KR20220127371A (ko) 2022-09-19
RS56012B1 (sr) 2017-09-29
AU2020202000A1 (en) 2020-04-09
SG10201709469SA (en) 2017-12-28
NZ713999A (en) 2020-11-27
SMT201700258T1 (it) 2017-07-18
AU2018223058A1 (en) 2018-09-20
CA2911536C (en) 2021-07-20
JP6415543B2 (ja) 2018-10-31
PH12015502563B1 (en) 2019-04-26
NZ753638A (en) 2020-11-27
PL3786162T3 (pl) 2024-04-08
CY1121763T1 (el) 2020-07-31
EA039660B1 (ru) 2022-02-24
EP3786162A1 (en) 2021-03-03
PH12018502125A1 (en) 2019-03-25
SI2997023T1 (sl) 2017-07-31
TWI885650B (zh) 2025-06-01
WO2014186706A1 (en) 2014-11-20
LT3231801T (lt) 2019-08-12
HRP20251220T1 (hr) 2025-12-05
KR102729910B1 (ko) 2024-11-15
US11591318B2 (en) 2023-02-28
CN107698569A (zh) 2018-02-16
FI3786162T3 (fi) 2023-10-02
EA202090291A2 (ru) 2020-05-31
EP2997023A1 (en) 2016-03-23
TWI840646B (zh) 2024-05-01
DK4275756T3 (da) 2025-09-29
MX385187B (es) 2025-03-14
PT4275756T (pt) 2025-10-31
NZ753637A (en) 2020-11-27
JP6775560B2 (ja) 2020-10-28
DK3231801T3 (en) 2019-04-15
US20140343030A1 (en) 2014-11-20
RS61482B1 (sr) 2021-03-31
EP4275756B1 (en) 2025-09-03
US9926301B2 (en) 2018-03-27
AU2020202000B2 (en) 2021-03-11
EA036448B1 (ru) 2020-11-11
CR20150633A (es) 2016-04-05
US10435392B2 (en) 2019-10-08
MY174788A (en) 2020-05-14
RS64591B1 (sr) 2023-10-31
AU2021202685B2 (en) 2022-11-17
ES2960731T3 (es) 2024-03-06
LT4275756T (lt) 2025-11-10
HRP20231048T1 (hr) 2023-12-22
HK1245769B (en) 2020-02-07
EP3231801B1 (en) 2019-02-13
US20250206726A1 (en) 2025-06-26
PE20160126A1 (es) 2016-02-24
PL2997023T3 (pl) 2017-08-31
PT3231801T (pt) 2019-05-24
PT2997023T (pt) 2017-05-31
UA117830C2 (uk) 2018-10-10
BR112015028501B1 (pt) 2022-11-01
IL282644B (en) 2021-10-31
PH12015502563A1 (en) 2016-02-22
LT3786162T (lt) 2023-11-27
PL3231801T3 (pl) 2019-07-31
BR112015028501B8 (pt) 2023-01-24
TR201905814T4 (tr) 2019-05-21
JP2024105557A (ja) 2024-08-06
ES3047826T3 (en) 2025-12-05
CN105452239B (zh) 2017-11-21
ES2845210T3 (es) 2021-07-26
PE20200527A1 (es) 2020-03-09
MX2020004506A (es) 2021-08-09
AU2014265279B2 (en) 2018-09-27
EA202090291A3 (ru) 2020-06-30
US20240150327A1 (en) 2024-05-09
CN107698569B (zh) 2020-11-27
MX373238B (es) 2020-05-08
EP2997023B1 (en) 2017-03-22
HUE043573T2 (hu) 2019-08-28
CR20190156A (es) 2019-05-16
ES2720073T3 (es) 2019-07-17
EP3527263A1 (en) 2019-08-21
FI4275756T3 (fi) 2025-10-20
CY1123756T1 (el) 2022-05-27
JP2016519147A (ja) 2016-06-30
IL282644A (en) 2021-06-30
CN105452239A (zh) 2016-03-30
CA2911536A1 (en) 2014-11-20
US20180312492A1 (en) 2018-11-01
EP3231801A1 (en) 2017-10-18
HRP20210119T1 (hr) 2021-03-05
US20200010456A1 (en) 2020-01-09
US12247020B2 (en) 2025-03-11
KR20160019905A (ko) 2016-02-22
TW201512191A (zh) 2015-04-01
US11001571B2 (en) 2021-05-11
AU2014265279A1 (en) 2015-11-26
IL264409A (en) 2019-02-28
KR102663357B1 (ko) 2024-05-14
ME02763B (me) 2018-01-20
LT3527263T (lt) 2021-05-10
DK3527263T3 (da) 2021-01-25
CL2015003355A1 (es) 2016-05-27
NZ753639A (en) 2020-11-27
IL287313B (en) 2022-03-01
AU2022263454A1 (en) 2022-12-08
DK3786162T3 (da) 2023-10-09
PT3786162T (pt) 2023-10-20
AU2021202685A1 (en) 2021-05-27
AR118120A2 (es) 2021-09-22
US20230159501A1 (en) 2023-05-25
MX2015015738A (es) 2016-03-16
TW202432140A (zh) 2024-08-16
TWI664176B (zh) 2019-07-01
BR112015028501A2 (pt) 2017-07-25
AR096330A1 (es) 2015-12-23
SI3231801T1 (sl) 2019-05-31
US20160289215A1 (en) 2016-10-06
HRP20170795T1 (hr) 2017-08-25
HUE063817T2 (hu) 2024-01-28
PL3527263T3 (pl) 2021-05-17
IL242453B (en) 2019-11-28
JP2022163162A (ja) 2022-10-25
EP2997023B9 (en) 2018-06-13
SI3527263T1 (sl) 2021-05-31
EP4620528A2 (en) 2025-09-24
IL287313A (en) 2021-12-01
KR102442747B1 (ko) 2022-09-14
US20210238168A1 (en) 2021-08-05
ES2626793T3 (es) 2017-07-26
AU2022263454B2 (en) 2024-01-18
TW202116320A (zh) 2021-05-01
KR20210120120A (ko) 2021-10-06
CY1119105T1 (el) 2018-02-14
ME03355B (me) 2019-10-20
HK1221466A1 (en) 2017-06-02
SG11201509180WA (en) 2015-12-30
SMT201900223T1 (it) 2019-07-11
EP3786162B1 (en) 2023-08-09
SMT202500397T1 (it) 2025-11-10
LT2997023T (lt) 2017-06-26
SI3786162T1 (sl) 2024-02-29
KR20240063187A (ko) 2024-05-10
TWI719401B (zh) 2021-02-21
US11905275B2 (en) 2024-02-20
AU2018223058B2 (en) 2020-01-02
TW201940479A (zh) 2019-10-16
HUE053122T2 (hu) 2021-06-28
HUE033587T2 (hu) 2017-12-28
EP3527263B1 (en) 2020-10-28
EA201592199A1 (ru) 2016-05-31
SMT202100040T1 (it) 2021-03-15
HRP20190713T1 (hr) 2019-06-14
EP4275756A3 (en) 2024-02-07

Similar Documents

Publication Publication Date Title
IL242453B (en) Bipyrazole derivatives as jak inhibitors
IL240863B (en) Amatoxin derivatives
SG11201506100XA (en) Pyridazinone-amides derivatives
ZA201506156B (en) Novel inhibitors
LT3027598T (lt) Oksochinazolinil-butanamido dariniai
IL240763B (en) The halopyrazoles as thrombin inhibitors
HUE037606T2 (hu) Imidazopirazinon-származékok